BiotechTube

LCZ696 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiomyopathy, Hypertrophic

Conditions

Cardiomyopathy, Hypertrophic

Trial Timeline

Jan 8, 2020 → Aug 22, 2023

NCT ID
NCT04164732

About LCZ696 + Placebo

LCZ696 + Placebo is a phase 2 stage product being developed by Novartis for Cardiomyopathy, Hypertrophic. The current trial status is completed. This product is registered under clinical trial identifier NCT04164732. Target conditions include Cardiomyopathy, Hypertrophic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04164732Phase 2Completed
NCT01193101Phase 2Completed

Competing Products

20 competing products in Cardiomyopathy, Hypertrophic

See all competitors
ProductCompanyStageHype Score
Tideglusib + PlaceboAMO PharmaPhase 2
44
MavacamtenLianBioPhase 1
25
Mavacamten + PlaceboLianBioPhase 3
69
CT-G20 + PlaceboCelltrionPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
85
AZD0233 + AZD0233 PlaceboAstraZenecaPhase 1
33
AZD4063AstraZenecaPhase 1
33
EplontersenAstraZenecaPhase 3
77
Eplontersen + PlaceboAstraZenecaPhase 3
77
candesartanAstraZenecaPhase 2
52
Darbepoetin alfaAmgenPre-clinical
22
Eleclazine + PlaceboGilead SciencesPhase 2/3
64
RanolazineGilead SciencesApproved
84
Ranexa + PlaceboGilead SciencesApproved
84
RanolazineGilead SciencesPre-clinical
22
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85